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Purpose: Stereotactic body radiotherapy (SBRT) is commonly used to treat unresectable
lung nodules. Given its relative safety and effective local control, SBRT has also been used
to treat recurrent lung nodules after high-dose external beam radiation (EBRT) to the lung.
The toxicity of such treatment is unknown.
Methods and Materials: Between 2006 and 2012, 18 subjects at the Mayo Clinic with 27
recurrent lung nodules were treated with SBRT after receiving EBRT to the lung. Median
local control, overall survival, and progression-free survival (PFS) were described. Acute
toxicity and late toxicity (defined as toxicity ≥ and >90 days, respectively) were reported
and graded as per standardized CTCAE 4.0 criteria.
Results: The median age of patients treated was 68 years. Fifteen patients had recurrent
lung cancer as their primary histology. Twelve patients received ≥60 Gy of conventional
EBRT prior to SBRT. SBRT dose and fractionation varied; the most common prescriptions
were 48 Gy/4, 54 Gy/3, and 50 Gy/5 fractions. Only four patients had SBRT planning tar-
get volumes (PTVs) that overlapped more than 50% of their prior EBRT PTV. Two patients
developed local recurrence following SBRT.With a median follow up of 21.2 months, median
SBRT-specific overall survival and PFS were 21.7 and 12.3 months, respectively. No grade
≥3 acute or late toxicities were noted.
Conclusion: Stereotactic body radiotherapy may be a good salvage option for select
patients with recurrent lung nodules following definitive EBRT to the chest. Toxicity is
minimal and local control is excellent.
Keywords: stereotactic body radiotherapy, reirradiation, external beam radiotherapy, lung cancer, toxicity tests,
acute, late toxicity
INTRODUCTION
Intrapulmonary recurrence or new T1-2N0 lung primaries after
definitive chemoradiation for locally advanced lung cancer is a
major clinical dilemma. Data from randomized trials indicate
locoregional recurrence may range from 30 to 40% with the major-
ity being in-field failures (1, 2). Previous experience with lung
reirradiation with conventional fractionated external beam radia-
tion (EBRT) for recurrent disease yields suboptimal local control
rates of 50–60% and 3–5% risk of grade 3 or higher toxicity (3).
For patients with recurrence localized to peripheral and central
locations, stereotactic body radiotherapy (SBRT) offers a potential
salvage option, which has low toxicity and optimal local control.
One of the earliest reports of stereotactic salvage RT for intra-
pulmonary/mediastinal recurrence has been described for 17
patients treated to a median dose of 32 Gy in 8 fractions (4).
Although the role of salvage RT was palliative, the crude local
control rate was 70% (4). Since 2005, lung SBRT has become
much more prevalent and higher hypofractionated doses are being
prescribed with curative intent. A number of retrospective single
institution reports suggest excellent local control rates exceeding
90% with limited follow up (5–8). The current study documents
our institution’s experience with SBRT post high-dose chest EBRT
with a median follow up of 21.2 months.
MATERIALS AND METHODS
Between 2006 and 2012, 18 patients with 27 recurrent lung nodules
were treated with SBRT after receiving EBRT to the chest. Patient
demographics including age, gender, tumor histology, chemother-
apy use, EBRT prescription, SBRT dose, number of lung nodules
treated, response to treatment, and acute and late treatment tox-
icity were collected. The data on SBRT treatment were collected
in a prospective manner and additional information was obtained
from retrospective chart review. Descriptive statistics were per-
formed using JMP (Version 9.01, SAS Institute Inc., Cary, NC,
USA).
Progression-free survival, overall survival, and follow up from
the end of SBRT treatment were estimated using the Kaplan–Meier
method. Progression-free survival (PFS) was defined as any local
or distant progression following the end of SBRT treatment. Local
failure was defined as in-field progression over serial CT-based
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imaging. Overall survival was calculated from the end of SBRT
treatment. RECIST criteria were applied prospectively as scans
became available to assess local control. This study was approved
by the Mayo Clinic Institutional IRB ethics board.
External beam radiation and SBRT plans were designed using
Eclipse (Varian, Palo Alto, CA, USA) treatment planning software.
All patients underwent 4DCT planning scans. The internal target
volume (ITV) was defined by contours on 10 phases of respiration.
Expansion from ITV to planning target volume (PTV) for SBRT
was 5 mm. Abdominal compression and breath-hold techniques
were employed to minimize motion where necessary.
Prior to 2010, most patients had planning performed using
3DCRT and static field intensity-modulated radiation therapy
(IMRT) techniques. After 2010, volumetric modulated arc therapy
(VMAT) planning was more frequently used. We have found no
treatment planning effect on local control or difference in toxicity
among all lung SBRT patients (9). Daily, cone beam CT was used
to verify the position of the ITV prior to each treatment delivery
for SBRT.
While data were available in a prospectively collected Mayo
Clinic SBRT database, all data were verified by retrospective chart
review. Acute and late toxicity data were documented at every fol-
low up in a prospective manner utilizing standard CTCAE version
4.03. Additional information was gathered from follow up notes
and notes documenting effects during the treatment course.
RESULTS
PATIENT, TUMOR, AND TREATMENT CHARACTERISTICS
The median age of patients was 68 years (range 20–76) and
most patients were female (n= 11). Seventeen of the 18 patients
included in the study had received prior definitive dose of lung
EBRT with the most common prescription being 60 Gy/30 frac-
tions. Of the 18 patients in the study, 14 patients were initially
treated for locally advanced non-small cell lung cancer (Stage IIIA
or IIIB; Table 1). PTV volumes for the initial EBRT ranged from
54 to 500 cc (median 254.7 cc). Four patients out of the 18 had
SBRT PTV that overlapped significantly (>50%) with their prior
EBRT PTV. Figure 1 shows an example of SBRT at a central site
that had nearly 100% overlap with prior high dose EBRT field.
Only four of the patients underwent biopsy to prove recurrence
prior to SBRT (Table 1) with the remaining SBRT courses deliv-
ered for presumptive recurrence based on serial CT enlargement
of a lung nodule and FDG avidity on PET–CT.
The median time between the end of EBRT and SBRT treatment
was 18.4 months (range 1.5–112.8 months). The median follow-
up period (from the end of SBRT to the time of last follow up) was
21.2 months (range 3.4–50.2 months). A total of 27 lung nodules
were treated in 18 patients with SBRT (Table 1). The median tumor
size and PTV volume treated with SBRT was 1.9 cm (range 0.5–
4.94 cm) and 19.2 cc (6.4–79.6 cc), respectively. The most common
dose prescriptions were 48 Gy/4, 50 Gy/5, and 54 Gy/3 fractions.
More than half of the lesions treated with SBRT (17/27) were
in the ipsilateral lung as the prior EBRT radiation field. Nine
patients received SBRT for central lung tumors. Most patients
only had one course of SBRT following EBRT (n= 13) and only
three patients received chemotherapy following SBRT treatment.
The three patients who received chemotherapy were continued on
Table 1 | Demographics of lung SBRT patients (N =18 patients; N =27
SBRT courses).
Median age (range in years) (N =18) 68 (20–76)
Gender (N =18)
Male 7
Female 11
Histology (N =18)
Sarcoma 2
Non-small cell lung cancer 14
Small cell lung cancer 1
Metastatic head and neck cancer 1
Chemotherapy use within 1 month of SBRT
(N =18)
Yes 3
No 15
Stage of NSCLC prior to SBRT (N =18)
T1N1 1
T1N2 1
T2N1 3
T2N3 1
TXN2 2
T2N2 3
T4NX 1
T4N1 1
T4N2 1
Unknown 4
Biopsy proven recurrence (N =27)
Yes 4
No 23
Median (range) time from EBRT to SBRT
(N =18)
18.4 months
(1.5–112.8)
Median (range) EBRT PTV Volume (N =18) 254.7 cc
(54.0–500.2 cc)
Prior EBRT prescription dose (N =18)
39 Gy/13# 1
45 Gy/30# (1.5 Gy BID) 1
48 Gy/12# 1
50 Gy/20# 1
50.4 Gy/28# 2
60 Gy/30# 7
64 Gy/32# 2
66 Gy/33# 2
70 Gy/35# 1
Median EBRT dose (N =18)
BED10 (range 51 to 84 Gy10) 72 Gy10
EQD2 (range 42.3 to 70 Gy) 60 Gy
Number of SBRT courses/patient (N =18)
1 12
2 5
3 1
(Continued)
Frontiers in Oncology | Radiation Oncology January 2015 | Volume 4 | Article 376 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Owen et al. SBRT post-EBRT in lung cancer
Table 1 | Continued
Median SBRTTumor Size (N =27) 1.9 cm (0.5–4.94 cm)
SBRT prescription dose (N =27)
40 Gy/5# 2
45 Gy/5# 1
48 Gy/4# 9
50 Gy/10# 1
50 Gy/5# 7
54 Gy/3# 6
60 Gy/3# 2
Median SBRT dose (N =27)
BED10 (range 72 to 180 Gy10) 105.6 Gy10
EQD2 (range 60 to 150 Gy) 88 Gy
Location of SBRT treatment (N =27)
Central 9
Peripheral 18
SBRT location relative to EBRT (N =27)
Ipsilateral 17
Contralateral 10
Response to treatment (based on imaging;
N =27)
CR 6
PR 12
Progression 1
SD 8
agents for lung adenocarcinoma, leiomyosarcoma, and Ewing sar-
coma. All were with palliative intent as all three patients developed
multiple lung metastases. Four patients received SBRT to tumors
that lay within the previous EBRT high-dose region (>50% over-
lap of previous EBRT 50% isodose line) with one patient whose
tumor recurred within the 95% isodose line.
DOSIMETRY OF CUMULATIVE EBRT AND SBRT PLANS
Cumulative lung dose was calculated using sum plans using the
Varian® eclipse planning software. The cumulative mean lung vol-
ume irradiated in all patients was 3320 cc with a mean DC1000 cc
(1000 cc of lung receiving a given dose or less) of 5.5 Gy and
DC1500 cc of 10.5 Gy. Mean lung V5 was 60.6% (median 62.4%)
and mean V20 was 29.5% (median 29.6%). The average mean
cumulative lung dose was (median 17.8 Gy; range 6.0–26.6 Gy).
The mean BED received by both lungs across cumulative EBRT and
SBRT courses was 187.7 Gy3 (range 99.8–356.2 Gy3). The average
mean heart dose was 21.6 Gy (median 23.6 Gy). Cumulative maxi-
mum dose to the esophagus and the chest wall ranged 38.9–78.4 Gy
(median 62.5 Gy) and 53.5–150.5 Gy (median 93.7 Gy), respec-
tively. Cumulative D4cc for bronchial tree ranged 20.1–79.6 Gy
(median 57.1 Gy).
ACUTE TOXICITY
Acute toxicity was any toxicity related to lung SBRT occurring
within 90 days of the start of SBRT. Median time to the develop-
ment of acute toxicity was 14.5 days (1–53 days range). Thirteen
FIGURE 1 | Sixty-eight-year-old man with locally advanced non-small
cell lung cancer (squamous cell histology) of the left upper lung
treated with neoadjuvant chemotherapy followed by definitive
chemoradiation (EBRT dose was 66 Gy/33 fractions to the left upper
lobe, low paratracheal, and left hilar nodes). (A) shows his radical EBRT
plan. He recurred 18 months later with an infield left hilar mass treated with
50 Gy/5 fractions using SBRT [(B) shows his SBRT plan]. Twelve months
later, he remains free of recurrent disease but has collapse of the left upper
lobe. He has no respiratory symptoms [(C) shows his most recent CT chest
and (D) shows his chest X-ray at 8 months after SBRT].
incidents of acute toxicity were documented in nine patients,
which were either grade 1 or 2. No grade 3 or higher toxicities
were noted. The most common toxicities were chest wall pain,
nausea, and fatigue. No dosimetric or patient factors were predic-
tors of acute toxicity. A summary of acute toxicities are noted in
Table 2.
LATE TOXICITY
Twelve late events (toxicity arising beyond 90 days from the end of
SBRT) were documented in eight patients. The median time to the
development of late toxicity was 176 days (range 88–493 days). All
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Table 2 | Acute toxicity (13 events in 9 patients).
Age (years) Gender Prior EBRT Dose SBRT dose SBRT courses Time to toxicity Grade+ toxicity
63 Female 48 Gy/12 fx 48 Gy/4 fx 3 1 day Grade 1 fatigue (counted as two separate
events as patient experienced this event
with two separate courses of SBRT)
60 Male 45 Gy/30 fx (1.5 Gy BID) 45 Gy/5 fx 1 1 day Grade 1 nausea
71 Female 60 Gy/30 fx 54 Gy/3 fx 1 1 day Grade 1 fatigue
64 Male 50.4 Gy/28 fx 54 Gy/3 fx 1 Unknowna Grade 1 nausea
76 Female 50 Gy/20 fx 50 Gy/5 fx 1 1 day Grade 1 cough
31 Male 60 Gy/30 fx 48 Gy/4 fx 1 Unknowna Grade 1 dyspnea
Unknowna Grade 1 chest wall pain
71 Female 64 Gy/32 fx 48 Gy/4 fx 1 53 days Grade 2 dyspnea
53 days Grade 2 chest wall pain
20 Male 50.4 Gy/28 fx 40 Gy/5 fx 2 33 days Grade 1 chest wall pain (counted as two
separate events as patient experienced this
event with two separate courses of SBRT)
64 Male 60 Gy/30 fx 50 Gy/5 fx 1 Unknowna Grade 1 nausea
aFor these four cases, the exact time to acute toxicity was unknown but the follow up notes by radiation oncology document these attributable effects <90 days from
the end of treatment.
Table 3 | Late toxicity (12 events in 8 patients).
Age (years) Gender Prior EBRT dose SBRT dose SBRT courses Time to toxicity Grade+ toxicity
63 Female 48 Gy/12 fx 48 Gy/4 fx 3 314 days Grade 1 dyspnea
60 Male 45 Gy/30 fx (1.5 Gy BID) 45 Gy/5 fx 1 158 days Grade 2 cough
Grade 2 dyspnea
71 Female 60 Gy/30 fx 54 Gy/3 fx 1 88 days Grade 1 dyspnea
64 Male 50.4 Gy/28 fx 54 Gy/3 fx 1 175 days Grade 2 radiation pneumonitis
76 Female 60 Gy/30 fx 54 Gy/3 fx 1 Unknowna Grade 1 fatigue
70 Female 60 Gy/30 fx 48 Gy/4 fx 1 253 days Grade 1 chest wall pain
493 days Grade 1 dyspnea
75 Female 64 Gy/32 fx 48 Gy/4 fx 1 Unknowna Grade 1 cough
Grade 1 dyspnea
70 Male 70 Gy/35 fx 48 Gy/4 fx 1 Unknowna Grade 2 chest wall pain
aFor these cases, the exact time to late toxicity was unknown but the follow up notes by radiation oncology document these attributable effects at greater than
90 days from the end of treatment.
were either grade 1 or 2. The most common late effect was dyspnea.
On univariate analysis, older age (p= 0.02) and chemotherapy
use following SBRT (p= 0.02) were associated with late toxicity.
None of the lung dosimetric parameters were predictive of late
toxicity. The development of acute toxicity was not predictive of
late toxicity. Site of tumor relative to prior EBRT volumes (ipsi-
lateral/contralateral lung), central/peripheral location, and over-
lapping volumes were also not predictive of late toxicity. Table 3
summarizes the late toxicities. There were inadequate patients and
events for multivariate analysis. Table 4 summarizes the univariate
analyses for predictors of both acute and late toxicity.
LOCAL CONTROL
Two of the 27 lesions recurred locally following salvage SBRT. One
was a central lesion and the other was a peripheral lesion. Actuarial
local control at 2 years was 90%. Given the very low failure rate,
it was not possible to examine any factors that predicted for local
failure.
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Table 4 | Univariate analysis of predictors of acute and late toxicity.
Factor Univariate
analysis
(p value) for
acute toxicity
Univariate
analysis
(p value) for
late toxicity
Age 0.79 0.02
Chemotherapy within 1 month
of SBRT
0.58 0.02
Right/left lung location 0.15 0.89
Central or peripheral lesion 0.34 0.91
Ipsilateral/contralateral recurrence
(compared to initial EBRT volume)
0.61 0.84
Time between EBRT and SBRT
courses
0.54 0.87
Number of SBRT courses 0.81 0.88
BED10 of SBRT course 0.45 0.74
Gender 0.14 0.61
OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL
Median SBRT OS (defined as survival from the date of completion
of SBRT) was 21.0 months (range 0.7–47 months) and median
SBRT PFS was 23.5 months (0.7–47 months). Actuarial 1 year OS
from the end of SBRT was 88% and SBRT-specific PFS at 1 year
was 58%.
DISCUSSION
The current study supports the potential use of lung SBRT as a
salvage modality after high-dose chest radiotherapy. With a local
control rate of 90% at 1 year and no grade 3 or higher toxicity
noted, SBRT was very well tolerated in our cohort of patients.
To date, there have been very few published reports of SBRT
treatment following high-dose chest EBRT. Coon et al. reported
on 12 patients who received 60 Gy in 3 fractions to recurrent
lung nodules post-EBRT treatment. With a median follow up of
12 months, no grade 3 or higher toxicity was reported and local
control was 92% at 1 year. The PTV volume treated was relatively
small (median of 14.3 cm3) (5, 10). The analysis of the retreated
patients was not extensive as they were included among 51 patients
who had received prior SBRT for solitary lung nodules.
Kelly et al. described the outcomes for 37 patients who received
SBRT following conventional radiotherapy for locally advanced
lung cancer (6). Their cohort received a single course of SBRT
to a solitary targeted lesion (median GTV size 1.7 cm, range
0.6–3.8 cm) (6). Most patients (n= 24) had previously received
60 Gy or higher and were retreated to 50 Gy in four fractions
(n= 26) (26/37). The dose fractionation was determined from
their prior study in which patients with T1 lesions post-EBRT
had better local control (100% at 2 years) with 50 Gy/4 fractions
than 40 Gy/4 fractions (local control 50%) (11). Two patients
had deliberate suboptimal SBRT coverage due to preservation
of critical structures for in-field recurrences (defined as within
the 30 Gy or 50% isodose line of the previous EBRT plan) (6).
With a median follow up of 15 months, the crude local control at
2 years was 95%. PFS at 2 years post-SBRT was 59% with 74% of
relapses occurring within the lungs (6). Similar to our study, their
treatment was very well tolerated with no acute toxicity. How-
ever, at least one grade 3 late toxicity was reported in 33% of
patients: radiation pneumonitis (n= 7), esophagitis (n= 3), skin
ulcer (n= 2), and cough (n= 1) (6, 10). Radiation pneumonitis
was not associated with in-field relapse. No grade 4 or 5 toxicities
were noted.
An update of the MD Anderson experience was published in
2012 on 74 patients, indicating that the practice of using SBRT
for new lung nodules or recurrent disease post-conventional chest
EBRT (median EBRT dose was 63 Gy with range of 30–79.2 Gy)
has been expanding (7). The focus of this study was on the inci-
dence and risk factors for severe radiation pneumonitis. Local
control remained excellent with only one patient experiencing in-
field failure post-SBRT. With a median follow up of 16 months,
the rate of grade 3 and above pneumonitis was 20.5% with one
patient experiencing grade 5 pneumonitis. Risk factors associ-
ated with radiation pneumonitis included pre-SBRT performance
status, the interval between EBRT and SBRT, ipsilateral versus con-
tralateral treatment with SBRT relative to EBRT, a history of severe
COPD (FEV1<65% predicted),previous treatment to the bilateral
mediastinum, and a cumulative V20 >39%. In the current study,
no grade 3 and above toxicities were noted and no dosimetric para-
meters were associated with the development of any pulmonary
toxicity (mostly grade 1 and grade 2 dyspnea). We did not routinely
perform PFTs in the reirradiation setting. In our study,one-third of
patients received more than one course of SBRT after conventional
radiation to the chest.
Most recently, Memorial Sloan Kettering has reported on their
experience of 39 patients (8). In this series, 22 patients had SBRT
PTVs that abutted or overlapped the 50% isodose line of prior
high-dose EBRT plans. There was a wide range of SBRT doses
used with less than half the patients (15) receiving BED≥100 Gy10.
With median follow up of 12.6 months, local PFS was 77% at 1 year.
This is much lower than in other published reports and in our cur-
rent study likely reflecting the reduction in BED10 for SBRT dosing
for post-EBRT in-field recurrences. Grade 3 and above toxicity was
quite low with two cases of grade 3 pneumonitis, two cases of grade
3 chest wall pain, and one case of grade 4 skin toxicity. There were
no grade 5 toxicities.
The current study shows excellent local control and very low
toxicity even in patients who received more than one course of
SBRT after conventionally fractionated high dose (≥60 Gy) EBRT
to the chest. However, the study is limited by its small number of
patients and its retrospective nature. Toxicity was not always col-
lected prospectively although radiographic response was collected.
Further, there was wide variability in the location of SBRT volumes
post-EBRT with the majority of patients not having significant
overlap of their previous EBRT PTV. As noted previously, only
four patients in our study had >50% overlap between the SBRT
and EBRT PTVs. This likely accounts for the low toxicity observed
in our study. Our patient cohort also had much higher overall
survival at 1 year (88%) than patients in other reports possibly
indicating a selection bias of good performance oligometastatic or
recurrent NSCLC patients.
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While the few reports on reirradiation with SBRT following
conventionally fractioned lung EBRT exist, they universally report
high rates of local control. However, the risk for adverse effects,
particularly severe radiation pneumonitis, is unclear. Studies in
which patients were treated with lower BED had a lower risk of
toxicity versus those in which most patients received high BED
treatments. As SBRT becomes more widely applied for local recur-
rence and metachronous or synchronous lung nodules in patients
who have been treated for locally advanced lung cancer, it will be
important to assess the outcomes of such patients in a prospec-
tive clinical trial with a dose escalation component embedded in
the trial design. Most recently, some institutions are exploring the
option of SBRT as a primary modality for dose painting and local-
ized boost after a lower dose of mediastinal or chest radiation
(45–60 Gy) (12, 13). While these early reports indicate that this
may be safe, guidance is needed to optimize or adapt SBRT dose
prescriptions and delivery especially in patients who may have
poor pre-existing lung function and significant overlap of their
EBRT and SBRT PTVs.
CONCLUSION
Stereotactic body radiotherapy can be an effective and safe sal-
vage option for patients who have a recurrence locally or within
the lung/mediastinum following high dose conventionally frac-
tionated EBRT for locally advanced lung cancer. SBRT appears
to be well tolerated but caution must be exercised as predictors
of toxicity and optimal risk-adapted SBRT dose prescriptions for
patients whose SBRT PTVs overlap their EBRT PTVs are not well
understood due to the limited experience. This question should be
studied in a prospective manner as the indications for lung SBRT
continue to expand.
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